Twist Bioscience Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
All right. So for our next panel here, happy to welcome Twist Biosciences for next fireside chat. With us, we have CFO, Jim Thorburn and Chief Commercial Officer, Patty Finn. Welcome.
Yes. I'm the CFO, and I've got the dull Scottish accent. Patty is Chief Commercial Officer and has got a more aggressive accent.
Questions & Answers
All right. So maybe dig in then from that there. So I guess Twist's portfolio touches on several fast-growing areas across antibody discovery, NGS, Synbio. I guess maybe talk from a high level, where do you see the largest near-term and maybe long-term opportunities across the portfolio?
Well, we just ended -- we just announced our quarter last week, last Friday seems like a long time ago. Revenue was $56 million for the quarter, and we had bookings orders almost $60 million. So in terms of orders,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
